Ionis Pharmaceuticals

Yahoo Finance • 49 minutes ago

CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Rothschild & Co Redburn upgraded Kenvue... Full story

Yahoo Finance • 4 hours ago

Analysts See 11% Upside For JHML

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 days ago

Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc (Symbol: IONS) was identified as having a larger market cap than the smaller end of the S&P 500, for example Align Tech... Full story

Yahoo Finance • 3 days ago

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application... Full story

Yahoo Finance • 8 days ago

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs)ThecaFlex DRx™ has the potential to be a new, convenient way... Full story

Yahoo Finance • 11 days ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • 15 days ago

Arrowhead sues Ionis over patent dispute related to lead asset

[Patent] JLGutierrez Arrowhead Pharmaceuticals (NASDAQ:ARWR [https://seekingalpha.com/symbol/ARWR]) sued Ionis Pharmaceuticals (NASDAQ:IONS [https://seekingalpha.com/symbol/IONS]) in a Delaware District Court on Wednesday as part of a pat... Full story

Yahoo Finance • 17 days ago

Ionis gets FDA breakthrough therapy status for angelman syndrome drug

[Neuron system disease] koto_feja/E+ via Getty Images * Ionis Pharmaceuticals (NASDAQ:IONS [https://seekingalpha.com/symbol/IONS]) said on Tuesday that the U.S. FDA has granted breakthrough therapy status to its antisense medicine, ION5... Full story

Yahoo Finance • 22 days ago

IONS Crosses Above Average Analyst Target

In recent trading, shares of Ionis Pharmaceuticals Inc (Symbol: IONS) have crossed above the average analyst 12-month target price of $44.08, changing hands for $44.27/share. When a stock reaches the target an analyst has set, the analyst... Full story

Yahoo Finance • 23 days ago

Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results

We recently published 10 Power Stocks Crushing Wall Street — 7 at All-Time Highs. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best performers on Tuesday. Ionis Pharmaceuticals soared to a new all-time high on Tuesday, as inves... Full story

Yahoo Finance • 24 days ago

Ionis to present at upcoming investor conferences

CARLSBAD, Calif., September 02, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo Healthcare Confer... Full story

Yahoo Finance • 24 days ago

Here are the top movers in Tuesday's session.

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 24 days ago

Stocks making the biggest midday moves: Frontier Group, Kraft Heinz, Biogen and more

Check out the companies making the biggest moves in midday trading: Frontier Group — Shares of the budget airline carrier shot up more than 13% in the wake of rival Spirit Airlines' bankruptcy filing on Friday. Humana — Shares of the healt... Full story

Yahoo Finance • 24 days ago

There are notable gap-ups and gap-downs in today's session.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT CARM... Full story

Yahoo Finance • 24 days ago

Ionis gains on late-stage trial win for hypertriglyceridemia therapy

[Doctor holding a test blood sample tube with Triglyceride test on the background of medical test tubes with analyzes] SyhinStas/iStock via Getty Images Ionis Pharmaceuticals (NASDAQ:IONS [https://seekingalpha.com/symbol/IONS]) added ~17%... Full story

Yahoo Finance • 27 days ago

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup

For technical investors looking for breakout chances, the method often requires finding stocks with both good basic technical condition and present consolidation patterns that indicate coming price action. This system uses two main measure... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Rise Pre-Bell Friday

Health care stocks were rising pre-bell Friday, with The Health Care Select Sector SPDR Fund (XLV) 0 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Ionis Pharmaceuticals stock price target raised to $43 by Stifel on Dawnzera approval

Investing.com - Stifel raised its price target on Ionis Pharmaceuticals (NASDAQ:IONS) to $43.00 from $38.00 while maintaining a Hold rating following the FDA approval of Dawnzera. The new target aligns closely with the stock’s current trad... Full story

Yahoo Finance • last month

US FDA approves Ionis' drug for rare genetic disorder

By Sneha S K and Bageshri Banerjee (Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals (NASDAQ:IONS)’ drug to prevent instances of severe swelling in various parts of the body of patients with a rar... Full story

Yahoo Finance • last month

Ionis Pharmaceuticals stock steady as BMO maintains Market Perform rating

Investing.com - BMO Capital reiterated its Market Perform rating and $40.00 price target on Ionis Pharmaceuticals (NASDAQ:IONS), currently trading at $43.19, following FDA approval of Dawnzera for HAE prophylaxis. According to InvestingPro... Full story